Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 10:8:94.
doi: 10.3389/fonc.2018.00094. eCollection 2018.

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

Ajaz Bulbul  1   2 , Hatim Husain  3
Affiliations
Review

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

Ajaz Bulbul et al. Front Oncol. .

Abstract

First generation or second generation EGFR tyrosine kinase inhibitors are currently the standard of care for the first-line management of non-small cell lung cancer (NSCLC) patients with activating mutations within the kinase domain of the epidermal growth factor receptor gene (1, 2). Resistance to targeted therapy can develop after 9-11 months (3-8). Third generation inhibitors were developed to target the EGFR T790M clone, which is the most common dominant second site resistance mutation after first or second generation inhibitors. Osimertinib received full FDA approval for the second-line treatment of advanced NSCLC based on a phase III study comparing the compound to chemotherapy. Recent data demonstrates an important impact for osimertinib in the front-line space based on results comparing the compound to first-generation erlotinib or gefitinib therapy.

Keywords: afatinib; epidermal growth factor receptor; erlotinib; gefitinib; lung cancer; osimertinib; targeted therapy.

PubMed Disclaimer

References

    1. Hanna N, Johnson D, Temin S, Baker S, Jr, Brahmer J, Ellis PM, et al. Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol (2017) 35(30):3484–515.10.1200/JCO.2017.74.6065 - DOI - PubMed
    1. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Giaj Levra M, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol (2016) 27:v1–27.10.1093/annonc/mdw326 - DOI - PubMed
    1. Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer (2017) 116:568–74.10.1038/bjc.2016.456 - DOI - PMC - PubMed
    1. Killock D. Lung cancer: a new generation of EGFR inhibition. Nat Rev Clin Oncol (2015) 12:373.10.1038/nrclinonc.2015.80 - DOI - PubMed
    1. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 31:3327–34.10.1200/JCO.2012.44.2806 - DOI - PubMed